Screener
Vir Biotechnology, Inc. VIR Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Personnel (2) | 28,512 | 33,165 | 60,040 | 66,883 |
| Clinical costs | 22,532 | 20,361 | 48,666 | 40,967 |
| Licenses, collaborations and contingent consideration, net | 41,211 | 11,301 | 38,402 | 47,892 |
| Other R&D (3) | 19,061 | 18,619 | 37,123 | 37,013 |
| Selling, general and administrative (2) | 30,196 | 22,283 | 53,535 | 46,227 |
| Restructuring, long-lived assets impairment and related charges, net | — | (172) | — | (182) |
| Plus: Other segment items (4) | 6,613 | 7,459 | 13,208 | 26,041 |
| Segment and consolidated net income (loss) | $80,080 | $(110,958) | $(45,615) | $(231,923) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s business segments — SG&A?
- Vir Biotechnology, Inc. (VIR) reported business segments — SG&A of $30.2M in Q2 2026.
- How has Vir Biotechnology, Inc.'s business segments — SG&A changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — SG&A increased by 35.5% year-over-year, from $22.28M to $30.2M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — SG&A?
- Over 2 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — SG&A has grown at a -24.6% compound annual growth rate (CAGR), from $161.76M to $92.07M.
- What does business segments — SG&A mean?
- Represents the overhead costs associated with the segment's administrative functions, legal, finance, and general corporate support. This metric is used to evaluate the operational efficiency and the cost structure of the business segment's non-research activities.
Ask your AI about Vir Biotechnology, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude